资讯

Healio10 小时
Dupilumab benefits patients with COPD, type 2 inflammation regardless of emphysema
Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...
Severe Asthma Market Set for Robust Growth Through 2034, Driven by Breakthrough Biologics ...
The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...
The Pharma Letter2 天
Dupixent demonstrated superiority over Xolair in chronic rhinosinusitis
French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...
GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, ...
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...
PMLive6 天
Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin ...
These are the first clinical study results for the drug in a large population of patients with darker skin tones ...